Philip Scheltens, M.D., Ph.D.

Alzheimer Center Amsterdam; Head EQT Life Sciences Dementia Fund

Contact Information

Philip Scheltens, M.D., Ph.D.
Amsterdam, Netherlands

Professional Information

Professor
Alzheimer Center Amsterdam; Head EQT Life Sciences Dementia Fund
http://www.alzheimercentrum.nl

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:
[Last updated: May 24, 2022]

Dr Scheltens has received consultancy fees (paid to the university)  from Alzheon, Brainstorm Cell and Green Valley. Within his university affiliation he is global PI of the phase 1b study of AC Immune, Phase 2b study with FUJI-film/Toyama and phase 2 study of UCB and phase 1 study with ImmunoBrain Checkpoint,. He is chair of the EU steering committee of the phase 2b program of Vivoryon, the phase 2b study of Novartis Cardiology and co-chair of the phase 3 study with NOVO-Nordisk. He is also an employee of EQT Life Sciences (formerly LSP).